CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

Is this finally the year CRISPR Therapeutics (NASDAQ: CRSP) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42% since ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

Additionally, Vertex will record 100 percent of CASGEVY revenues; costs of sales; and selling, general and administrative expenses and will record CRISPR’s 40 percent share in the net profits or ...

In Q3, Casgevy approval was secured in Switzerland and Canada, with approval in Kuwait and United Arab Emirates ("UAE") expected by end of year. The drug is already approved in US, UK, Europe.

While Casgevy is currently the only CRISPR-based therapy, several companies are advancing gene-editing treatments using similar technology. Beam Therapeutics BEAM is developing its lead candidate ...